David A. Reardon

David A. Reardon

Auto-generated profile, based on publicly available information

David A. Reardon

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
DRDavid A. Reardon
David A. Reardon
ABAlba A. Brandes
Alba A. Brandes
AOAntonio Omuro
Antonio Omuro
PMPaul Mulholland
Paul Mulholland
MLMichael Lim
Michael Lim
MWMichael Weller
Michael Weller
Glioblastoma has a poor prognosis, with a 5-year survival rate of less than 10%.1,2 Nearly all patients experience recurrence following standard-of-care surgical resection, radiotherapy, and temozolomide.2-4 Treatment options at recurrence are limited, and no therapy has prolonged overall survival (OS) in this setting, which underscores the need for novel therapeutic interventions in this patient population.4

19 December 2018 in Nature
Verified
Journal Article
Closed access
PDF file
DKDerin B. Keskin
Derin B. Keskin
AAAnnabelle J. Anandappa
Annabelle J. Anandappa
JSJing Sun
Jing Sun
ITItay Tirosh
Itay Tirosh
NMNathan D. Mathewson
Nathan D. Mathewson
DRDavid A. Reardon
David A. Reardon

1 November 2015 in The Lancet Oncology
Verified
Journal Article
Open access
HOHideho Okada
Hideho Okada
MWMichael Weller
Michael Weller
RHRaymond Huang
Raymond Huang
GFGaetano Finocchiaro
Gaetano Finocchiaro
MGMark R Gilbert
Mark R Gilbert
DRDavid A Reardon
David A Reardon
Immunotherapy is a promising area of therapy in patients with neuro-oncological malignancies. However, early-phase studies show unique challenges associated with the assessment of radiological changes in response to immunotherapy reflecting delayed responses or therapy-induced inflammation. Clinical benefit, including long-term survival and tumour regression, can still occur after initial disease progression or after the appearance of new lesions. Refinement of the response assessment criteria for patients with neuro-oncological malignancies undergoing immunotherapy is therefore warranted. Herein, a multinational and multidisciplinary panel of neuro-oncology immunotherapy experts describe immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria based on guidance for the determination of tumour progression outlined by the immune-related response criteria and the RANO working group. Among patients who demonstrate imaging findings meeting RANO criteria for progressive disease within 6 months of initiating immunotherapy, including the development of new lesions, confirmation of radiographic progression on follow-up imaging is recommended provided that the patient is not significantly worse clinically. The proposed criteria also include guidelines for the use of corticosteroids. We review the role of advanced imaging techniques and the role of measurement of clinical benefit endpoints including neurological and immunological functions. The iRANO guidelines put forth in this Review will evolve successively to improve their usefulness as further experience from immunotherapy trials in neuro-oncology accumulate.

20 November 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PWPatrick Y. Wen
Patrick Y. Wen
MBMartin J. Van Den Bent
Martin J. Van Den Bent
GYGilbert Youssef
Gilbert Youssef
TCTimothy F Cloughesy
Timothy F Cloughesy
BEBenjamin M. Ellingson
Benjamin M. Ellingson
SCSusan M. Chang
Susan M. Chang
PURPOSE: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS: Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS: We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION: The revised RANO 2.0 criteria refine response assessment in gliomas.

1 March 2021 in Cell
Verified
Journal Article
Closed access
NMNathan D. Mathewson
Nathan D. Mathewson
OAOrr Ashenberg
Orr Ashenberg
ITItay Tirosh
Itay Tirosh
SGSimon Gritsch
Simon Gritsch
EPElizabeth M. Perez
Elizabeth M. Perez
KWKai W. Wucherpfennig
Kai W. Wucherpfennig

1 February 2016 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
DRDavid A. Reardon
David A. Reardon
PGPrafulla C. Gokhale
Prafulla C. Gokhale
SKSarah R. Klein
Sarah R. Klein
KLKeith L. Ligon
Keith L. Ligon
SRScott J. Rodig
Scott J. Rodig
GFGordon J. Freeman
Gordon J. Freeman
Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated exciting and durable remissions across a spectrum of malignancies. Combinatorial regimens blocking complementary immune checkpoints further enhance the therapeutic benefit. The activity of these agents for patients with glioblastoma, a generally lethal primary brain tumor associated with significant systemic and microenvironmental immunosuppression, is not known. We therefore systematically evaluated the antitumor efficacy of murine antibodies targeting a broad panel of immune checkpoint molecules, including CTLA-4, PD-1, PD-L1, and PD-L2 when administered as single-agent therapy and in combinatorial regimens against an orthotopic, immunocompetent murine glioblastoma model. In these experiments, we observed long-term tumor-free survival following single-agent anti–PD-1, anti–PD-L1, or anti–CTLA-4 therapy in 50%, 20%, and 15% of treated animals, respectively. Combination therapy of anti–CTLA-4 plus anti–PD-1 cured 75% of the animals, even against advanced, later-stage tumors. In long-term survivors, tumor growth was not seen upon intracranial tumor rechallenge, suggesting that tumor-specific immune memory responses were generated. Inhibitory immune checkpoint blockade quantitatively increased activated CD8+ and natural killer cells and decreased suppressive immune cells in the tumor microenvironment and draining cervical lymph nodes. Our results support prioritizing the clinical evaluation of PD-1, PD-L1, and CTLA-4 single-agent targeted therapy as well as combination therapy of CTLA-4 plus PD-1 blockade for patients with glioblastoma. Cancer Immunol Res; 4(2); 124–35. ©2015 AACR.